Show simple item record

dc.contributor.authorWaddington, Claire
dc.contributor.authorCarey, Megan E
dc.contributor.authorBoinett, Christine J
dc.contributor.authorHigginson, Ellen
dc.contributor.authorVeeraraghavan, Balaji
dc.contributor.authorBaker, Stephen
dc.date.accessioned2022-03-21T02:03:00Z
dc.date.available2022-03-21T02:03:00Z
dc.date.issued2022-02-16
dc.identifier.issn1756-994X
dc.identifier.other35172877
dc.identifier.otherPMC8849018
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/335248
dc.description.abstractAntimicrobial resistance (AMR) is a major global public health threat, which has been largely driven by the excessive use of antimicrobials. Control measures are urgently needed to slow the trajectory of AMR but are hampered by an incomplete understanding of the interplay between pathogens, AMR encoding genes, and mobile genetic elements at a microbial level. These factors, combined with the human, animal, and environmental interactions that underlie AMR dissemination at a population level, make for a highly complex landscape. Whole-genome sequencing (WGS) and, more recently, metagenomic analyses have greatly enhanced our understanding of these processes, and these approaches are informing mitigation strategies for how we better understand and control AMR. This review explores how WGS techniques have advanced global, national, and local AMR surveillance, and how this improved understanding is being applied to inform solutions, such as novel diagnostic methods that allow antimicrobial use to be optimised and vaccination strategies for better controlling AMR. We highlight some future opportunities for AMR control informed by genomic sequencing, along with the remaining challenges that must be overcome to fully realise the potential of WGS approaches for international AMR control.
dc.languageeng
dc.publisherSpringer Science and Business Media LLC
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourcenlmid: 101475844
dc.sourceessn: 1756-994X
dc.subjectVaccines
dc.subjectGenomics
dc.subjectAntimicrobial resistance
dc.subjectSurveillance
dc.subjectPublic Health
dc.subjectDiagnostics
dc.subjectAnimals
dc.subjectHumans
dc.subjectAnti-Infective Agents
dc.subjectAnti-Bacterial Agents
dc.subjectDrug Resistance, Bacterial
dc.titleExploiting genomics to mitigate the public health impact of antimicrobial resistance.
dc.typeArticle
dc.date.updated2022-03-21T02:03:00Z
prism.issueIdentifier1
prism.publicationNameGenome Med
prism.volume14
dc.identifier.doi10.17863/CAM.82679
dcterms.dateAccepted2022-02-04
rioxxterms.versionofrecord10.1186/s13073-022-01020-2
rioxxterms.versionVoR
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidBaker, Stephen [0000-0003-1308-5755]
dc.identifier.eissn1756-994X
pubs.funder-project-idWellcome Trust (215515/Z/19/Z)
cam.issuedOnline2022-02-16


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International